Scientific value is hard to finance through traditional routes
BioVergence is building the infrastructure to identify, structure, finance, and selectively commercialize scientific assets more intelligently.
Biotech, pharma, diagnostics, and emerging science programs often sit between research promise and financeability. We are building the rails that connect evidence, market demand, contributors, and capital formation in one system.
Why BioVergence
A live platform thesis
Onboarding $100M+ in bioscience assets ranging from GLP-1 variants to regenerative therapeutics.
A larger market
Scientific assets need broader, more structured access to capital than bespoke private deals and fragmented licensing pathways typically allow.
Built on real infrastructure
BioVergence is being assembled on a Swiss legal and structuring foundation with partner rails across tokenization, custody, compliance, AI, and manufacturing.
A repeatable structure
We are building a standard path for making scientific assets machine-readable, rankable, financeable, and eventually tradeable.
A community and AI advantage
BioVergence combines contributor intelligence, dataset enrichment, and AI-driven underwriting to improve both asset selection and commercialization.
Protected infrastructure
Our approach is supported by patented and related intellectual-property strategy around scientific asset formation, rights structuring, and financial infrastructure.
Projects
The platform
One ecosystem, many rails into scientific capital
BioVergence ecosystem
Assets, IP, Revenue into Real World Assets
Our first live tokenization pilot, with Griffon Pharmaceutical, is already underway.
Share insights, earn rewards (coming soon)
Developing novel peptides, GLP-1, & more
Tokenization turns a right into a digital instrument that can be owned, tracked, and transferred.
Facilitate collaborations and licensing across institutions.
Create new funding and investment opportunities.
Enable and reward community participation.
One protocol, many assets, many parties.
See where you fit in.
Meet our Leaders
Science is full of brilliance, but it is and has been held back by broken systems.
In labs around the world, breakthroughs sit dormant. Intellectual property gathers dust. Funding flows unevenly. Scientists are stuck in legacy silos. Licensing is slow, opaque, and often extractive. And despite historic advancements in technology, most research struggles to make it out of PDFs, let alone into products or public hands.
So, why not make intellectual assets recombinable? Why not make research and data sets remixable?
BioVergence is set out to build an entirely new engine for scientific innovation, one rooted in openness, modularity, and decentralization. We're accelerating innovation and changing who gets to participate in it, who gets rewarded by it, and how fast it reaches the world.
Where we're heading
Built for global impact
We're laying the groundwork for a new scientific economy. Our goal is to unlock thousands of modular ventures, catalyze billions in recombined IP value, and activate a global network of contributors.
Pipeline projects currently in development
Consortium members by 2027
Tokenized IP assets by 2027
Size of the global bioconvergence market
Our Values
Modular by Design
We build systems, assets, and communities to be flexible, remixable, and future-proof.
Modular by Design
We build systems, assets, and communities to be flexible, remixable, and future-proof.
Science as Infrastructure
We treat knowledge as a building block, not a byproduct--ready to scale, combine, and deploy.
Science as Infrastructure
We treat knowledge as a building block, not a byproduct--ready to scale, combine, and deploy.
Incentive Drives Impact
We align rewards with contribution, ensuring value flows to those who create it.
Incentive Drives Impact
We align rewards with contribution, ensuring value flows to those who create it.
FAQ
Frequently asked questions
Frequently asked questions
Frequently asked questions
What is your tokenization process?
Where do the scientific assets come from?
Who is BioVergence for?
How do I get started?
Scientific value is hard to finance through traditional routes
BioVergence is building the infrastructure to identify, structure, finance, and selectively commercialize scientific assets more intelligently.
Biotech, pharma, diagnostics, and emerging science programs often sit between research promise and financeability. We are building the rails that connect evidence, market demand, contributors, and capital formation in one system.
Why BioVergence
A live platform thesis
Onboarding $100M+ in bioscience assets ranging from GLP-1 variants to regenerative therapeutics.
A larger market
Scientific assets need broader, more structured access to capital than bespoke private deals and fragmented licensing pathways typically allow.
Built on real infrastructure
BioVergence is being assembled on a Swiss legal and structuring foundation with partner rails across tokenization, custody, compliance, AI, and manufacturing.
A repeatable structure
We are building a standard path for making scientific assets machine-readable, rankable, financeable, and eventually tradeable.
A community and AI advantage
BioVergence combines contributor intelligence, dataset enrichment, and AI-driven underwriting to improve both asset selection and commercialization.
Protected infrastructure
Our approach is supported by patented and related intellectual-property strategy around scientific asset formation, rights structuring, and financial infrastructure.
Projects
The platform
One ecosystem, many rails into scientific capital
BioVergence ecosystem
Assets, IP, Revenue into Real World Assets
Our first live tokenization pilot, with Griffon Pharmaceutical, is already underway.
Share insights, earn rewards (coming soon)
Developing novel peptides, GLP-1, & more
Tokenization turns a right into a digital instrument that can be owned, tracked, and transferred.
Facilitate collaborations and licensing across institutions.
Create new funding and investment opportunities.
Enable and reward community participation.
One protocol, many assets, many parties.
See where you fit in.
Meet our Leaders
Science is full of brilliance, but it is and has been held back by broken systems.
In labs around the world, breakthroughs sit dormant. Intellectual property gathers dust. Funding flows unevenly. Scientists are stuck in legacy silos. Licensing is slow, opaque, and often extractive. And despite historic advancements in technology, most research struggles to make it out of PDFs, let alone into products or public hands.
So, why not make intellectual assets recombinable? Why not make research and data sets remixable?
BioVergence is set out to build an entirely new engine for scientific innovation, one rooted in openness, modularity, and decentralization. We're accelerating innovation and changing who gets to participate in it, who gets rewarded by it, and how fast it reaches the world.
Where we're heading
Built for global impact
We're laying the groundwork for a new scientific economy. Our goal is to unlock thousands of modular ventures, catalyze billions in recombined IP value, and activate a global network of contributors.
Pipeline projects currently in development
Consortium members by 2027
Tokenized IP assets by 2027
Size of the global bioconvergence market
Our Values
Modular by Design
We build systems, assets, and communities to be flexible, remixable, and future-proof.
Modular by Design
We build systems, assets, and communities to be flexible, remixable, and future-proof.
Science as Infrastructure
We treat knowledge as a building block, not a byproduct--ready to scale, combine, and deploy.
Science as Infrastructure
We treat knowledge as a building block, not a byproduct--ready to scale, combine, and deploy.
Incentive Drives Impact
We align rewards with contribution, ensuring value flows to those who create it.
Incentive Drives Impact
We align rewards with contribution, ensuring value flows to those who create it.
FAQ